Kintara Therapeutics Operating Income 2010-2024 | HURA

Kintara Therapeutics operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Kintara Therapeutics Operating Income 2010-2024 | HURA

Kintara Therapeutics operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$172.8B
Vertex Pharmaceuticals (VRTX)$124.7B
Regeneron Pharmaceuticals (REGN)$109.2B
Gilead Sciences (GILD)$108B
Bristol Myers Squibb (BMY)$107.9B
CSL (CSLLY)$97.9B
GSK (GSK)$79.9B
Alnylam Pharmaceuticals (ALNY)$38B
Argenex SE (ARGX)$33.8B
Biogen (BIIB)$27.7B
BioNTech SE (BNTX)$26.6B
Illumina (ILMN)$23.3B
BeiGene (BGNE)$21.3B
Moderna (MRNA)$20.8B
Genmab (GMAB)$15.2B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13.3B
Vaxcyte (PCVX)$12.9B
Insmed (INSM)$12.8B
Incyte (INCY)$12.8B
Sarepta Therapeutics (SRPT)$12.1B
Bio-Techne Corp (TECH)$11.3B
QIAGEN (QGEN)$9.8B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.8B
Revolution Medicines (RVMD)$8.4B
Intra-Cellular Therapies (ITCI)$8.3B
Exelixis (EXEL)$8.2B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.9B